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Objectives The purpose of this study was to establish the incidence of and risk factors for sudden cardiac death (SCD) in
pediatric dilated cardiomyopathy (DCM).
Background The incidence of SCD in children with DCM is unknown. The ability to predict patients at high risk of SCD will
help to define who may benefit most from implantable cardioverter-defibrillators.
Methods The cohort was 1,803 children in the PCMR (Pediatric Cardiomyopathy Registry) with a diagnosis of DCM from
1990 to 2009. Cumulative incidence competing-risks event rates were estimated. We achieved risk stratification
using Classification and Regression Tree methodology.
Results The 5-year incidence rates were 29% for heart transplantation, 12.1% non-SCD, 4.0% death from unknown
cause, and 2.4% for SCD. Of 280 deaths, 35 were SCD, and the cause was unknown for 56. The 5-year inci-
dence rate for SCD incorporating a subset of the unknown deaths is 3%. Patients receiving antiarrhythmic medi-
cation were at higher risk of SCD (hazard ratio: 3.0, 95% confidence interval: 1.1 to 8.3, p  0.025). A risk strat-
ification model based on most recent echocardiographic values had 86% sensitivity and 57% specificity. Thirty of
35 SCDs occurred in patients who met all these criteria: left ventricular (LV) end-systolic dimension z-score 2.6,
age at diagnosis younger than 14.3 years, and the LV posterior wall thickness to end-diastolic dimension ratio
0.14. Sex, ethnicity, cause of DCM, and family history were not associated with SCD.
Conclusions The 5-year incidence rate of SCD in children with DCM is 3%. A risk stratification rule (86% sensitivity) included
age at diagnosis younger than 14.3 years, LV dilation, and LV posterior wall thinning. Patients who consistently
meet these criteria should be considered for implantable cardioverter-defibrillator placement. (Pediatric
Cardiomyopathy Registry; NCT00005391) (J Am Coll Cardiol 2012;59:607–15) © 2012 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.10.878In adults, sudden cardiac death (SCD) accounts for sub-
stantial mortality in nonischemic cardiomyopathy, with
deaths from congestive heart failure (CHF) and SCD
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trials have demonstrated a survival benefit with the use of
implantable cardioverter-defibrillators (ICDs) in this pop-
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Association/American College
of Cardiology guidelines recom-
mend ICD placement in adults
with nonischemic dilated cardio-
myopathy (DCM) who have a
left ventricular ejection fraction
(LVEF) 35% and are in New
York Heart Association func-
tional class II or III (5).
The estimated annual inci-
dence of DCM in children is
0.57 cases per 100,000, and the
overall prognosis is poor, with
40% of children undergoing car-
diac transplantation or dying
within 5 years after diagnosis (6).
However, the incidence of SCD
is low based on single-center re-
ports, yet little information is
available on risk factors for SCD
(7,8). Therefore, there are no established criteria for the use
of ICDs for the primary prevention of SCD in children with
DCM.
We determined the incidence and risk factors for SCD
using data in a large multicenter cohort of children with DCM.
We analyzed the association of demographic, clinical, and
echocardiographic characteristics with SCD. We sought to
identify the characteristics of children who may benefit from
ICD placement for the primary prevention of SCD.
Methods
Study design. The PCMR (Pediatric Cardiomyopathy
Registry) has enrolled 3,500 infants, children, and ado-
lescents with cardiomyopathy younger than 18 years of age
at diagnosis from nearly 100 pediatric cardiac centers in
North America. Children were enrolled retrospectively if
they were diagnosed with cardiomyopathy between 1990
and 1995 and prospectively thereafter (9,10). Annual re-
porting continues until death or heart transplantation.
All centers obtained institutional review board approval
for participation in the PCMR.
Study sample. All enrolled patients with DCM in the
PCMR met at least 1 of the following criteria (10): 1) strict
echocardiographic criteria for DCM (left ventricular [LV]
dilation [i.e., LV end-diastolic dimension [EDD] 2 SD
above normal for body surface area] and depressed LV
systolic function [LV fractional shortening or LVEF 2
SD below normal for age]); 2) pathologic findings consis-
of this publication are solely the responsibility of the authors and do not necessarily
represent the official views of the NHLBI. Dr. Hsu is a consultant for Berlin Heart
Inc. All other authors have reported that they have no relationships relevant to the
contents of this paper to disclose.
Abbreviations
and Acronyms
CART  classification and
regression tree
CHF  congestive heart
failure
DCM  dilated
cardiomyopathy
EDD  end-diastolic
dimension
ICD  implantable
cardioverter-defibrillator
LV  left ventricular
LVEF  left ventricular
ejection fraction
LVPWT 
left ventricular posterior
wall thickness
SCD  sudden cardiac
deathr
Manuscript received August 3, 2011; revised manuscript received October 11,
2011, accepted October 31, 2011.tent with DCM at autopsy or by endomyocardial biopsy; or
3) other clinical evidence of DCM provided by the
cardiologist.
Children with specific secondary causes of myocardial
abnormalities were excluded, which included but were not
limited to associated congenital heart disease, endocrine
disorders known to cause myocardial damage, a history of
chemotherapy or pharmacology-associated cardiotoxicity,
chronic arrhythmia, pulmonary parenchymal or vascular
disease, and immunologic disease.
SCD definition. SCD was defined as an unexpected death
occurring 1 h after the onset of a symptomatic cardiac
event. The circumstances of death were abstracted from the
medical record. Three pediatric cardiologists (E.P., C.E.C.,
S.D.C.) reviewed the autopsy report where available and the
abstracted notes for all deaths to ensure consistent classifi-
cation. All deaths were classified as either SCD, cardiac
death that was non-SCD, or unknown.
Measurements. Demographic information, clinical evi-
dence of CHF, New York Heart Association functional
class, family history of cardiomyopathy, medication classes,
and other therapies were recorded from the time of cardio-
myopathy diagnosis and annually. Echocardiographic mea-
surements were collected from the clinical study performed
at the time of presentation and from the most recent clinical
echocardiogram obtained during each annual reporting
period. These included LV EDD, LV end-systolic dimen-
sion, LV fractional shortening, LV septal and LV posterior
wall thicknesses, LV mass, and the presence of tricuspid or
mitral regurgitation. Information regarding the use of med-
ications other than anticongestive therapy, ICD implanta-
tion, valvar regurgitation grade, atrial enlargement, and
electrocardiographic, and Holter monitoring findings were
primarily collected on retrospectively enrolled patients. In
addition, LVEF data collection was limited.
Statistical methods. All data were analyzed by the Data
Coordinating Center at the New England Research Insti-
tutes, Watertown, Massachusetts. Descriptive statistics in-
clude counts and percentages for categorical data, median
and interquartile range for highly skewed data, and mean 
D for normally distributed data. We used mean imputa-
ion for all echocardiographic values except LVEF, which
as missing for two-thirds of patients. Echocardiographic
-scores were calculated relative to body surface area (LV
DD, LV end-systolic dimension, LV end-diastolic poste-
ior wall and septal thicknesses, and M-mode–derived LV
ass) or relative to age (LV fractional shortening and
VEF) (11). Electrocardiographic and Holter monitoring
ata, available in less than one third of subjects, were used
n univariate analysis only without imputation.
The primary outcome was SCD. The cumulative inci-
ence rates of SCD, non-SCD, unknown cause of death,
nd transplantation were estimated using competing risks
ethodology (12). The 56 deaths of unknown cause were
xcluded from risk factor analysis. Cox proportional hazards
egression modeling was used to identify univariate risk
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of all children not experiencing SCD were censored at the
date of last known date alive, non-SCD, or transplantation.
Candidate predictors included measures from the time of
cardiomyopathy diagnosis as well as echocardiographic
measurements from the latest available echocardiogram. We
developed risk prediction models using recursive partition-
ing (classification and regression tree [CART]), for the
presence or absence of SCD (13). We adopted this ap-
proach rather than multivariable regression modeling, in
which the patient subgroups required to construct interac-
tion terms would require pre-specification. CART creates
nonparametric discriminating trees by dividing patients
repeatedly into subgroups, each representing subjects with a
low versus high risk of SCD.
Alpha was set at 0.05, and all tests were 2 tailed. Analyses
were conducted using SAS version 9.1 (SAS Institute Inc.,
Cary, North Carolina) and R and S-PLUS version 8.0
(Insightful Corporation, Seattle, Washington).
Results
As of February 2009, the PCMR included 1,803 children
with a diagnosis of DCM since 1990. Causes of DCM
determined at presentation were idiopathic disease (n 
1,286), myocarditis (n 255), neuromuscular disorder (n
136), malformation syndrome (n  10), familial isolated
ardiomyopathy (n  78), and inborn error of metabolism
n  38). Mean age at diagnosis was 5.3  6.1 years. Mean
V EDD z-score was 4.3  2.7, LV fractional shortening
as 16 9%, and LVEF (n 597) was 28 14%. Median
ollow-up in patients with no death or transplantation event
as 2.6 years (interquartile range, 0.8 to 5.3 years; maxi-
um, 16.7 years).
vent rates. Of 280 deaths, the type of death was SCD in
5 (13%), non-SCD in 189 (68%), and unknown in 56
20%). Thus, among patients with a known mode of death,
6% were SCD (35 of 224). Among the 1,747 survivors and
hose with a known cause of death, SCD comprised 1.9%.
he majority of SCDs, 74% (n  26), occurred 2 years
after presentation. Most non-SCDs were caused by CHF.
The incidence rate of SCD was low, and the rates of
transplantation and non-SCD were high. The 1-, 3-, and
5-year cumulative incidence rates were 1.3%, 2.0%, and
2.4%, respectively (95% CI: 1.7% to 3.4%) for SCD. The
1-, 3-, and 5-year cumulative incidence rates for non-SCD
were 8.1%, 10.8%, and 12.1%, and 22%, 27%, and 29%,
respectively, for heart transplantation (Fig. 1). In addition,
the 5-year incidence of death of unknown cause (n  56)
was 4%. If the proportion of patients who experienced SCD
in the group with an unknown cause of death is similar to
that in the patients with a known cause of death (16%; 32 of
225), then we estimate that 9 additional patients experi-
enced SCD, and the 5-year cumulative incidence of SCD is
3.0%. This group of 56 patients is not included in risk factor
analyses.Risk factors for SCD: predictors from the time of
cardiomyopathy diagnosis. SCD was not associated with
sex, race/ethnicity, or cause of DCM (Table 1). Children
who experienced SCD were more likely to present with
CHF (86%) at diagnosis than children who did not expe-
rience SCD (73%, hazard ratio: 2.84; p  0.03). In the first
month after diagnosis, 47% of the SCD group and 22% of
all other children were on antiarrhythmic therapy (hazard
ratio: 3.00, 95% confidence interval: 1.08 to 8.30; p 0.03).
Family history of SCD, family history of cardiomyopathy,
New York Heart Association functional class, and use
anticongestive or beta-blocker agents in the first month
after diagnosis were not associated with SCD. Among the
subset of 548 patients who had information on ICD
therapy, only 9 had an ICD, and none experienced SCD.
We examined echocardiographic parameters obtained at
presentation (Table 1). Compared with patients without
SCD, patients with SCD had a lower (log-transformed)
LVPWT to EDD ratio, an index of ventricular remodeling
that is a surrogate for LV end-diastolic wall stress, with a
low ratio indicating insufficient LV hypertrophy (p  0.02).
A larger LV posterior wall thickness z-score was protective
against SCD (hazard ratio: 0.86, p  0.047). Fractional
Figure 1 Competing Risk Analysis: Outcomes
in Children With Dilated Cardiomyopathy
Competing risks analysis for sudden cardiac death, non-sudden cardiac death,
unknown cause of death, and cardiac transplantation among 1,803 children with
dilated cardiomyopathy (DCM) listed in the Pediatric Cardiomyopathy Registry. The
3-, 5-, and 10-year cumulative incidence rates (95% confidence interval) of sudden
cardiac death are estimated to be 2.0% (1.4% to 2.8%), 2.4% (1.7% to 3.4%), and
2.7% (1.8% to 3.9%), respectively; of non–sudden cardiac death, 10.8% (9.3% to
12.4%), 12.1% (10.4% to 13.9%), and 14.9% (12.6% to 17.3%), respectively; and
of heart transplantation, 27% (25% to 29%), 29% (27% to 32%), and 31% (28% to
34%), respectively. The rate of death of unknown cause (95% confidence interval)
was 3.4% (2.6% to 4.5%), 4.0% (3.0% to 5.2%), and 5.2% (3.6% to 7.3%).shortening z-score was not a risk factor (p  0.33).
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SCD
(n  35)
All Others
(n  1,712) Hazard Ratio (95% CI) p Value
Retrospective cohort 28.6 25.3 1.13 (0.53–2.42) 0.752
Age at diagnosis, yrs 4.7 5.6 5.3 6.1 0.99 (0.94–1.05) 0.738
Male 54.3 53.5 1.05 (0.54–2.05) 0.880
Race/ethnicity 0.649
White 62.9 55.3 2.42 (0.33–17.93)
Black 22.9 21.0 2.55 (0.32–20.37)
Hispanic 11.4 16.9 1.46 (0.16–13.04)
Other 2.9 6.8 —
Idiopathic 77.1 71.6 1.55 (0.70–3.41) 0.279
CHF at diagnosis 85.7 72.6 2.84 (1.10–7.35) 0.031
NYHA functional class IV 0.139
Yes 34.3 23.8 1.79 (0.70–4.56)
No 20.0 19.6 Ref
Unknown 45.7 56.5 0.85 (0.35–2.07)
Family history of cardiomyopathy 0.551
Yes 11.4 12.1 0.74 (0.25–2.18)
No 51.4 44.9 Ref
Unknown 37.1 43.0 0.68 (0.33–1.39)
Family history of sudden death 0.905
Yes 5.7 6.0 0.86 (0.20–3.70)
No 54.3 52.7 Ref
Unknown 40.0 41.3 0.86 (0.43–1.72)
Anticongestive therapy
Yes 88.6 82.2 1.60 (0.57–4.55) 0.375
No 11.4 14.3 Ref
Unknown 0 3.5 —
Antiarrhythmic therapy 0.025
Yes 20.0 12.1 3.00 (1.08–1.30)
No 22.9 41.4 Ref
Unknown 57.1 46.5 3.00 (1.31–6.86)
ACE inhibitor 0.023
Yes 20.0 38.3 0.38 (0.14–1.06)
No 22.9 18.5 Ref
Unknown 57.1 43.2 1.30 (0.56–2.98)
Beta-blocker 0.090
Yes 2.9 7.0 0.30 (0.04–2.27)
No 40.0 48.0 Ref
Unknown 57.1 45.0 2.05 (1.02–4.11)
LV end-diastolic dimension z-score 4.2 2.3 4.3 2.4 1.01 (0.88–1.16) 0.928
LV end-systolic dimension z-score 5.9 2.2 6.0 2.5 1.01 (0.88–1.16) 0.883
LV fractional shortening z-score 8.8 2.5 8.5 3.4 0.95 (0.85–1.06) 0.332
LV end-diastolic posterior wall thickness
z-score
1.1 2.8 0.5 2.0 0.86 (0.74–1.00) 0.047
LV end-diastolic septal wall thickness
z-score
1.1 1.1 0.8 1.5 0.84 (0.68–1.05) 0.123
LV mass z-score 2.0 2.7 2.3 2.8 0.98 (0.84–1.14) 0.766
LVEF z-score* 6.9 2.5 6.0 2.4 0.76 (0.55–1.05) 0.094
Raw LVEF* 23.3 14.6 28.5 13.7 0.95 (0.90–1.01) 0.073
LVEF 35%* 8 (80.0) 330 (67.8) 2.69 (0.57–12.69) 0.213
Raw LV fractional shortening, % 15.3 6.2 16.0 8.3 0.97 (0.93–1.02) 0.298
LV fractional shortening 18% 27 (77.1) 1249 (73.0) 1.55 (0.70–3.41) 0.282
Log (ratio of LV posterior wall thickness:
end-diastolic dimension)
2.24 0.38 2.13 0.32 0.28 (0.10–0.79) 0.016Continued on next page
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February 7, 2012:607–15 Sudden Death in Pediatric Dilated CardiomyopathyWe also examined electrocardiographic and Holter find-
ings from the latest available follow-up. Of the 35 SCD
patients, 13 had an electrocardiogram but only 5 had
quantitative data, with a mean QTc interval of 449  72
s. None of the 5 had any degree of atrioventricular block.
ne of the patients had a notation for wide complex tachy-
ardia. These findings were qualitatively very similar to those in
he 531 non-SCD patients who had QTc data (428 50 ms),
ith 5% (21 of 441) having atrioventricular block (none third
egree). Holter data were available for 5 of 35 SCD patients,
ith 3 of 5 (60%) having ventricular tachycardia and 60%
aving ventricular couplets. In the non-SCD group, 18% (52
f 294) had ventricular tachycardia, and 25% (75 of 295) had
entricular couplets. No patients in either group had third-
egree heart block or atrioventricular block. These limited data
ere not used in multivariable analysis.
Multivariable CART analysis based on predictors from
he time of DCM diagnosis demonstrated that the LV
osterior wall thickness z-score, age at diagnosis, and LV
eptal thickness z-score and antiarrhythmic therapy are the
ost important discriminators between SCD and non-
CD (Fig. 2). Overall, 2% of subjects had SCD. Two of the
subgroups in the regression tree have at least twice the risk of
CD (e.g., 4 %). These include: 1) patients with LV
osterior wall thickness z-score 1.7; and 2) patients with
V posterior wall thickness z-score 1.7, age at diagnosis
ounger than 13.1 years, septal thickness z-score 0.8, and
hose who were prescribed antiarrhythmic therapy within a
onth of presentation with DCM. This model classified 24%
f patients as high risk (i.e., 20 of 35 deaths occurred in these
roups), yielding 57% sensitivity and 78% specificity. Due to
he very low prevalence of SCD, the positive predictive value
percentage of % SCD among those identified as high risk) was
nly 5%, whereas the negative predictive value (percentage of
on-SCD among those identified as lower risk) was 99%.
isk factors for SCD: predictors from last available
ollow-up. Because treatment decisions are made based
n the most current status of the patient, we also
xamined the predictive strength of the latest available
ContinuedTable 1 Continued
SCD
Moderate to severe tricuspid
regurgitation
Yes 8.6
No 14.3
Unknown 77.1
Moderate to severe mitral
regurgitation, %
Yes 14.3
No 11.4
Unknown 74.3
Values are %, mean  SD, or n (%). *Imputation was not used for LVE
10 for SCD group and 485 for all others.
ACE  angiotensin-converting enzyme; CHF  congestive heart fa
ejection fraction; NYHA  New York Heart Association; Ref  refereneasures of LV size and function. More than three- rourths (78%) of subjects had at least 1 follow-up
easurement (range, 1 to 17). For the remainder, their
alue from the time of diagnosis was used.
Univariate analysis (Table 2) shows that a higher risk of
CD was significantly associated with all echocardiographic
arameters except for LV posterior wall and septal thick-
esses. For LV EDD and mass, a unit increase in z-score
as associated with a 1.2- to 1.3-fold increase in risk.
imilarly, a 5-unit decrease in LV fractional shortening (%)
r LVEF (%) imparted a 1.4- to 1.5-fold increase in the risk
f SCD. The LVPWT:EDD ratio was again highly pre-
ictive (p  0.001). At least moderate mitral (3% of
atients) or tricuspid (8% of patients) regurgitation was also
ssociated with SCD.
Multivariable CART analysis that considered echocar-
iographic measurements from the most recent follow-up
except for LVEF, see the Methods section) in addition to
ge and the presence of CHF at diagnosis demonstrated
hat LV end-systolic dimension z-score, age at diagnosis,
nd LVPWT:EDD ratio are the most important discrimi-
ators between SCD and non-SCD (Fig. 3). The tree had 4
erminal nodes. Three nodes had a below-average rate of SCD
0% to 1.8%). A single node captured 30 of the 35 SCD. This
ubgroup (44% of patients) with the highest SCD rate
3.9%, 30 of 766) met all 3 of the following criteria: 1) LV
nd-systolic dimension z-score 2.6; 2) DCM diagnosis at
ge younger than 14.3 years; and 3) LVPWT:EDD ratio
0.14. This patient subset produced high sensitivity of 86%
30 of 35) and specificity of 57% (981 of 1,712), albeit with
positive predictive value of 4% and a negative predictive
alue of 99%.
Despite the LVEF from follow-up being available for only
6% of patients, we examined the predictive strength of LVEF
35%, a commonly used threshold, and assessed its validity by
omparing it with the equivalent value of LV fractional
hortening 18%. The results for these 2 thresholds were
imilar (Table 2). If an LVEF 35% is used as an indication
or ICD placement, sensitivity is only 73% (compared with the
Others Hazard Ratio (95% CI) p Value
0.078
3.7 4.73 (1.13–19.80)
26.3 Ref
69.9 2.46 (0.93–6.51)
0.176
9.3 3.33 (0.89–12.40)
20.9 Ref
69.9 2.39 (0.82–6.95)
LVEF n  10 for SCD group and 487 for all others. LVEF z-score n 
 confidence interval; LV  left ventricular; LVEF  left ventricular
p for hazard; SCD  sudden cardiac death.All
F. Rawegression tree result in Figure 3 with 86% sensitivity). Spec-
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he regression tree (57%).
iscussion
ncidence of SCD. Our first goal was to determine the
ncidence of SCD in a large cohort of well-characterized
hildren with DCM. We found that the 5-year cumulative
ncidence of known SCD in patients with DCM is 2.4%. If
he proportion of SCD in the patients who died of un-
nown causes was similar to the proportion in the patients
ho died of known causes, the estimated 5-year incidence
ate of SCD is 3%. In a series of 85 children with DCM
mean LVEF, 25%), only 1 child (1%) died suddenly (7). In
ulticenter study of SCD by Rhee et al. (14) in 2,392
hildren with DCM and congenital heart disease listed for
ransplantation, the incidence of SCD was low (1.3%), and
nly those patients with ischemic cardiomyopathy had an
ncreased risk of SCD (relative risk, 6.92).
The incidence of SCD is well below the rates reported in
dults with DCM (15). In the DEFINITE (Defibrillators
n Non-Ischemic Cardiomyopathy Treatment Evaluation)
rial, SCD occurred in 7.4% of 458 adults with DCM (with
Figure 2 Classification and Regression Tree for SCD
Predictors from time of cardiomyopathy diagnosis (N  1,747, 35 sudden cardiac
denote lower risk patient subgroups. Sensitivity  57%, specificity  78%. False-pVEF 36%); the mortality rate at 2 years was 14.1% in the Dtandard therapy group (annual mortality of 7%) compared
ith 7.9 % in the ICD group (2). Thus, in children with
CM, in contrast to adults, SCD is rare, and death caused
y progressive CHF is more common (7,15,16). The reason
or this lower incidence in SCD is unclear, but may be due
o several factors. Children have fewer ventricular arrhyth-
ias documented by ambulatory Holter monitoring than do
dults with idiopathic DCM (1–3,5,7,8). Fibrosis has been
hown to correlate with ventricular arrhythmias and SCD
17), and children with DCM may have less fibrosis than
dults with DCM due to age-related factors as well as
ge-dependent comorbidities such as diabetes and hyper-
ension. These comorbidities in adults lead to diastolic
ysfunction that may have additive effects that lead to more
entricular arrhythmias in adults with DCM; thus, DCM in
hildren may have a different natural history than that in
dults. Our study has shown that deaths in children with
CM are typically due to CHF or graft loss occurring from
ransplantation rather than SCD, suggesting a different
athophysiology than in adults. More research with bio-
arkers and genotype-phenotype correlations will be nec-
ssary to better define the natural history that differentiates
s [SCD]). Red boxes denote high-risk patient groups. Bold black boxes
rate  95%, false-negative rate  1.1%. LV  left ventricular.death
ositiveCM presenting in children from that observed in adults.
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February 7, 2012:607–15 Sudden Death in Pediatric Dilated CardiomyopathyRisk factors for SCD: factors known at diagnosis. Our
second goal was to develop a risk stratification rule to identify
children at high risk of SCD to aid clinicians in identifying
those patients who may benefit from ICD placement. Sex,
race/ethnicity, cause of DCM, family history, and LV frac-
tional shortening were not independent risk factors. Our
multivariable CART analysis showed that 24% of children fell
into a high-risk group based solely on factors known at
presentation. One high-risk group was defined solely by a
thin-walled left ventricle at presentation (LV posterior wall
thickness z-score 1.7) and the other by patients with LV
wall thickness above this cutoff but who received a diagnosis
before 13.1 years, had a thin LV septum, and were prescribed
antiarrhythmic therapy in the month that DCM was diag-
nosed. These findings stress the value of intraventricular septal
thickness and LV posterior wall thickness observed early in the
course of DCM in children. Basing ICD implantation deci-
sions on these criteria captured more than one-half of patients
who went on to have SCD.
The use of antiarrhythmic medications within 30 days of
presentation was a risk factor for SCD in the CART
analysis tree as well as in the univariate analysis. The type of
antiarrhythmic agent was not collected for most subjects.
Arrhythmia in adults with poor LV function is a risk factor
for SCD and has been used as an indication for placing
ICDs, and children with a history of sustained ventricular
tachycardia or ventricular fibrillation are more likely to
Patient Characteristics by SCD Status Using Measurements Fromand Univariate Cox Regression ResultsTable 2 Pa ient Characteristic by SCD Statu Using Measureand Univariate Cox Regression Results
SCD
CHF 77.1
Echocardiographic measurements
LV end-diastolic dimension z-score 4.8 2.6
LV end-systolic dimension z-score 6.3 2.4
LV fractional shortening z-score 8.2 3.5
LV end-diastolic posterior wall thickness z-score 0.6 2.2
LV end-diastolic septal thickness z-score 1.1 1.1
LV mass z-score 2.6 2.3
LV ejection fraction z-score* 6.3 1.6
Raw LV ejection fraction, %* 27.0 8.8
LV ejection fraction 35%* 11 (73.3)
Raw LV fractional shortening 16.2 8.5
LV fractional shortening 18% 25 (71.4)
Log (ratio of LV posterior wall thickness:
end-diastolic dimension)
2.2 0.30
Moderate to severe tricuspid regurgitation
Yes 17.1
No 11.4
Unknown 71.4
Moderate to severe mitral regurgitation
Yes 5.7
No 20.0
Unknown 74.3
Values are %, mean  SD, or n (%). *Raw LVEF n  15 for SCD group and 789 for all others. LVE
Abbreviations as in Table 1.undergo ICD placement. In our study, arrhythmia data were pnot consistently collected and 24-h Holter monitoring data
were not routinely available, so these could not be examined as
risk factors. A single-center study of 63 children with DCM
found that 46% had arrhythmias; the majority were atrial, and
only 6 had ventricular tachycardia (8). Death occurred in 4 of
the 29 children with known arrhythmias; however, only 1 of
these children died suddenly.
Of note, moderate to severe tricuspid and mitral insuffi-
ciency at latest follow-up were more frequently identifiable
in the SCD cohort on univariate analysis. Tricuspid regur-
gitation typically correlates with more severe CHF and is
likely a surrogate for pulmonary hypertension (18).
Risk factors for SCD: last available follow-up. With the
use of clinical information from the last available follow-up, we
constructed a risk stratification model with high sensitivity
(86%) and moderate specificity (57%). A single node of the
CART captured 30 of the 35 SCDs. These patients had an
increased systolic ventricular size (LV end-systolic dimension
z-score2.6) indicating abnormal dilation, were younger than
4 years old at diagnosis, and had a decreased LVPWT:EDD
atio (0.14). This prediction rule is easy to use and based on
easurements performed (or calculable) from routine echocar-
iography. A lower LVPWT:EDD ratio was also found in
nivariate analyses to be associated with the composite end-
oint of all-cause mortality and transplantation in the PCMR
CM cohort (6). We hypothesize that patients with a low
VPWT:EDD ratio may have an insufficient LV hypertro-
ast Follow-Ups From the Last Follow-Up
All Others Hazard Ratio (95% CI) p Value
50.6 7.89 (3.47–17.96) 0.002
3.3 2.8 1.31 (1.17–1.48) 0.001
4.4 3.5 1.30 (1.17–1.44) 0.001
5.4 4.8 0.78 (0.71–0.86) 0.001
0.7 2.1 1.05 (0.91–1.23) 0.494
0.9 1.7 0.94 (0.76–1.15) 0.532
1.6 2.4 1.21 (1.10–1.32) 0.001
5.1 2.4 0.69 (0.57–0.83) 0.001
33.7 14.1 0.94 (0.91–0.97) 0.001
336 (42.6) 8.67 (2.71–27.72) 0.001
22.1 12.0 0.92 (0.88–0.95) 0.001
789 (46.1) 5.63 (2.64–11.97) 0.001
2.1 0.3 0.19 (0.08–0.46) 0.001
0.001
7.9 9.86 (2.76–18.94)
33.1 Ref
58.9 6.26 (2.07–18.94)
0.005
2.8 6.44 (1.32–31.29)
38.3 Ref
59.0 4.09 (1.66–10.07)
re n  15 for SCD group and 787 for all others.the Lmenthic response to compensate for the LV dilation caused by the
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ciated changes in the risk of SCD is recommended because a
patient’s echocardiographic measurements of LV size may
worsen or improve over time.
This risk stratification model may be used independently
or in conjunction with the first at diagnosis tree to identify
children with DCM who are at higher risk of SCD for
whom increased monitoring is appropriate. If the first tree
(rule) is used, then 24% of children with DCM would
receive an ICD at the time of diagnosis of cardiomyopathy.
With the use of the second tree, eventually 44% of subjects
might receive an ICD, with only 4% of those receiving an
ICD truly at risk of an event—that is, 26 patients would
undergo ICD implantation to prevent 1 event of SCD.
Considerable tradeoffs therefore continue to exist with
respect to ICD placement, but our estimated low incidence
of SCD combined with the ability to moderately discrimi-
nate risk levels suggests that universal ICD implantation in
the pediatric DCM population is probably not warranted.
Whether ICDs could be beneficial in higher risk children is
unclear. In a review of ICD databases at 9 heart transplantation
centers, Dubin et al. (19) reported that 28 patients received
ICDs while awaiting transplantation (16 had DCM). Of
these, 42% had an appropriate discharge; however, the
incidence of inappropriate ICD discharge was 25%.
The model presented here provides evidence that ICD
implantation is not indicated for all children presenting with
DCM and demonstrates that those at highest risk can be
Figure 3 Classification and Regression Tree for SCD
Predictors from time of last follow-up (N  1,747, 35 SCDs). Red box denotes the
Sensitivity  86%, specificity  57%. False-positive rate  96%, false-negative raidentified. However, the successful identification of the chil- Vdren at highest risk of SCD, a relatively rare event, lacks
specificity, with 26 ICD implantations required to prevent 1
SCD. Therefore, recommendations for ICD placement in
children must be considered in conjunction with the concom-
itant anxiety related to inappropriate shocks, as well as an
increased likelihood of complications such as lead fractures and
the need for frequent lead and defibrillator replacement, and
body size issues that necessitate epicardial rather than trans-
venous systems in smaller children (20). Clinical decision
making is a continuous process and uses cumulative evidence
regarding a patient’s condition that is garnered across multiple
follow-ups. If a child who received a diagnosis of DCM before
14 years of age consistently meets all the criteria that indicate
a high risk of SCD (abnormal LV end-systolic dimension
z-score and LVPWT:EDD ratio 0.14), ICD implantation
hould be considered. Definitive criteria for ICD use in
hildren must await clear evidence of improved survival based
n these criteria.
tudy limitations. First, 56 of 280 deaths did not have an
dentifiable cause of death. Although some of these deaths
ay have been sudden rather than due to CHF, we
ypothesize that, for most, it is a random sample of deaths
ith missing information. Therefore, we reported a second-
ry estimate of SCD incidence that incorporated 16% of the
eaths with unknown cause into the event rate estimate.
he estimated 5-year rate was still only 3%.
Another limitation is the lack of information about the
ncidence of ventricular arrhythmias in this population.
risk patient group. Bold black boxes denote lower risk patient subgroups.
.6%. Abbreviations as in Figure 2.high-
te  0entricular arrhythmias are a risk factor for SCD in adults
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data available had undergone an ICD placement; thus, it is
unlikely that ventricular arrhythmias were common in this
population. Furthermore, unlike in adult patients, invasive
electrophysiologic stimulation is not performed routinely in
children to assess the risk of sustained monomoprhic ven-
tricular tachycardia. Therefore, it is possible that the com-
ponents of the risk stratification model would differ if this
information were available.
Similarly, electrocardiographic and Holter monitoring
data were not included in our multivariable analyses because
they were collected for 15% of the SCD patients and less
than one-third of the patients without SCD. Some of the
missing data are due only to the timing of the data collection
protocol and thus are possibly missing at random; however,
other causes of not undergoing electrocardiography or
Holter monitoring that may render those with data to be a
nonrepresentative subset cannot be dismissed.
We chose to use CART methodology, due in part to the
visual appeal of the classification tree and ease of interpre-
tation and application for clinicians. However, we note as a
limitation that CART has been shown to have a similar and
not necessarily superior predictive power relative to other
risk stratification methods, such as logistic regression and
machine learning approaches (21). If our data were analyzed
using a different approach, it is possible that a different set
of discriminatory factors might be identified. The final
limitation is that the risk stratification models presented
have not been validated using an independent dataset.
Application of these models to other DCM cohorts will
provide needed evidence of its accuracy and reliability.
Conclusions
The 5-year incidence of SCD in children with DCM does
not exceed 3%, a rate much lower than in adults. Indepen-
dent predictors of SCD include echocardiographic features
of both LV thinning and dilation, the LVPWT:EDD ratio,
use of antiarrhythmic therapy within 1 month of diagnosis,
and age at diagnosis before 13 to 14 years. SCD can be
predicted with 86% sensitivity, although with lower speci-
ficity (57%), and requires 26 ICD implantations to prevent
1 SCD. Our data support the concept that universal
implantation of ICDs is probably not warranted. However,
risk stratification is possible and is strengthened by a
patient’s condition meeting all the high-risk criteria for an
extended period. In such situations, ICD placement should
be considered for pediatric patients with DCM.
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